Newly Described Bacteria Enhances Efficacy of Immune Checkpoint Blockade
Major Finding: The microbiomes of patients that respond to anti–PD-1 are enriched for a newly described bacterial strain, YB328.Concept: YB328 promotes the maturation and migration of CD103+CD11b– cDCs and enhances CD8+ T-cell activation.Impact: This study suggests that YB328, a bacteria present in many human microbiomes, may be leveraged to improve immunotherapy.
Publication Details
- Journal
- Cancer Discovery
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1158/2159-8290.cd-rw2025-070
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00